DOI: 10.1101/19010223Oct 25, 2019Paper

Endocrine therapy use and the risk of cardiovascular disease in postmenopausal breast cancer survivors: two cohort studies in the UK and US

MedRxiv : the Preprint Server for Health Sciences
Anthony MatthewsKrishnan Bhaskaran


Objective: Examine the effect of tamoxifen and aromatase inhibitors on 12 clinically relevant individual cardiovascular outcomes in postmenopausal female breast cancer survivors using large-scale datasets from the UK and US. Design: Two prospective cohort studies Setting: Population-based using data from the UK Clinical Practice Datalink linked with Hospital Episode Statistics (2002-2016), and the US Surveillance, Epidemiology and End Results-Medicare database (2008-2013). Participants: 10005 and 22027 postmenopausal women with breast cancer in the UK and US respectively. Exposures: Aromatase inhibitor compared with tamoxifen use; the US cohort additionally included a comparison with an unexposed group of women with oestrogen or progesterone receptor positive breast cancer but no endocrine therapy use. Outcomes: 12 clinically relevant individual cardiovascular outcomes (and two composite coronary and venous thromboembolic outcomes) Results: In both the UK and the US, there was evidence of an increased risk of coronary artery disease in aromatase inhibitor compared with tamoxifen users (UK incidence rate: 10.18 vs 6.87 per 1000 person-years, HR: 1.29, 0.94-1.76; US incidence rate: 35.26 vs 26.95 per 1000 person-years, HR: 1.29, ...Continue Reading

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.